Clinical efficacy of TNF-α inhibitors: An update

International Journal of Clinical Rheumatology

Volumn 5, Issue 1, 2010, Pages 101-115

  Ozer, Huseyin Te ^a   Ozbalkan, Zeynep ^b  

^a CUKUROVA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adalimumab; Ankylosing spondylitis; Anti TNF ; Arthritis; Etanercept; Infliximab; Inhibitors; Juvenile rheumatoid arthritis; Psoriatic; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTHRITIS; BEHCET DISEASE; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRANULOMATOUS INFECTION; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; KINESIOTHERAPY; LATENT TUBERCULOSIS; LISTERIOSIS; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; LYMPHOMA; NAIL DISEASE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DEFECT; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VIRUS LOAD;

EID: 77950270955     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.70     Document Type: Review

References (133)

1. Maini RN, Breedveld FC, Kalden JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti TNF monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
2. Ikeda K, Cox S, Emery P: Biological therapy in early arthritis- overtreatment or way to go? Arthritis Res. Ther. 9(211), 1-7 (2007).
3. Caporali R, Pallavicini FB, Filippini M et al.: Treatment of rheumatoid arthritis with anti-TNF-a agents: a reappraisal. Autoimmun. Rev. 8, 274-280 (2009).
4. O'Dell J: Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350, 2591-2602 (2004).
5. Choi EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
6. Moss ML, Sklair-Tavron L, Nudelman R: Drug insight: tumor necrosis factor converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4(6), 300-309 (2008).
7. Hochberg MC: "Stepping-up" from methotrexate: a systemic review of randomized placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann. Rheum. Dis. 60(3), 51-54 (2007).
8. Voulgari PV, Drosos AA: Adalumimab for rheumatoid arthritis. Expert Opin. Biol. Ther. 13, 1349-1360 (2006).
9. Gartlehner G: The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta analysis. J. Rheumatol. 33, 2398-2408 (2006).
10. Chang J, Girgis L: Clinical use of anti TNF-a biological agents. A guide for GPs. Aust. Fam. Physician 36, 1035-1038 (2007).
11. Furst DE, Breedveld FC, Kalden JR et al.: Updated consensus statement on Biological agents, specifically tumour necrosis factor (a) blocking agents and interleukin-1 receptor antagonist (IL-1), for the treatment of rheumatic diseases. Ann. Rheum. Dis. 64 (Suppl. 4), 2-14 (2005).
12. Firestein GS: Pathogenesis of rheumatoid arthritis: how early is early? Arthritis Res. Ther. 7, 157-159 (2005).
13. Quinn MA, Emery P: Window of opportunity in early rheumatoid arthritis: possible of altering the disease process with early intervention. Clin. Exp. Rheumatol. 21(5), 154-157 (2003).
14. Raza K, Buckley CE, Salmon M, Buckley CD: Treating very early rheumatoid arthritis. Best Pract. Res. 20, 849-863 (2006).
15. Bathon JM, Martin RW, Fleischmann RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
16. Breedveld FC, Weisman MH, Kavanaugh AF et al.: The PREMIER study. A multicentre, randomized, double blind clinical trial of combination therapy with adalumimab plus methotrexate versus methotrexate alone or adalumimab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).
17. Smolen JS, Van Der Heije DM, St Clir EW et al.: Predictors of joint damage in patients with early rheumatoid arthritis treated with high dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702-710 (2006).
18. Smolen JS, Han C, Bala M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52, 1020-1030 (2005).
19. Reinhart K, Karzai W: Anti TNF therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29(Suppl.), 121-125 (2001).
20. Quinn MA, Conaghan PG, O'Connor PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage with sustained benefit after infliximab withdrawal: results from a twelve month randomized double blind placebo controlled trial. Arthritis Rheum. 52, 27-35 (2005).
21. Goekoop Ruiterma YP, de Viries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study) a randomized controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
22. van Dongen H, van Aken JJ, Lard L et al.: A double-blind randomized clinical trial in patients with undiffrentiated arthritis: the Probable Rheumatoid Arthritis: Methotrexate Versus Placebo Treatment (PROMPT) study. Arthritis Rheum. 56, 1424-1432 (2007).
23. Visser H, le Cessie S, Vos K et al.: How to diagnose rheumatoid arthritis early: prediction model for persistent (erosive) arthritis. Arthritis Rheum. 46, 357-365 (2002).
24. Conaghan PG, Mc Queen FM, Peterfy CG et al.: The evidence for MRI as an outcome measure in proof-of-concept rheumatoid arthritis studies. J. Rheumatol. 32, 2465-2469 (2005).
25. Wakefield RJ, Gibbon WW, Conaghan PG et al.: The value of sonography in detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiograph. Arthritis Rheum. 43, 2762-2770 (2000).
26. Hochberg MC, Lebwohl MG, Plevy SE et al.: The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin. Arthritis Rheum. 34, 819-836 (2005).
27. Lam J, Takeshita S, Barker JE et al.: TNF induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of rheumatoid arthritis NK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
28. Redlich K, Hayer S, Ricci R et al.: Osteoclasts are essential for TNF-a mediated joint destruction. J. Clin. Invest. 1110, 1419-1427 (2002).
29. Williams EL, Gadola S, Edwards CJ: Anti-TNF-induced lupus. Rheumatology (Oxford) 48(7), 716-720 (2009).
30. Winthrop KL: Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nature 2(11), 602-610 (2006).
31. Bekker LG: TNF-a controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J. Immunol. 166, 6728-6734 (2001).
32. Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FQ: TNF-a mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected g interferon-activated macrophages. Infect. Immun. 63, 4862-4867 (1995).
33. Jüttner S, Bernhagen J, Metz CN, Röllinghoff M, Bucala R, Gessner A: Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-a. J. Immunol. 161, 2383-2390 (1998).
34. Rothe J, Lesslauer W, Lötscher H et al: Mice lacking TNF receptor 1 are resistant to TNF mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993).
35. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH: Tumor necrosis factor-a receptor I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 67, 595-601 (1999).
36. Moore TA, Lau HY, Cogen AL, Standiford TJ: Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia. Tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-a. Clin. Infect. Dis. 41(3), 213-217 (2005).
37. QuantiFERON-tb Gold® , Product information. Cellestis, CA, USA
38. Dixon WG, Hyrich KL, Watson KD et al.: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. (2009) (Epub ahead of print).
39. Tubach F, Salmon D, Ravaud P et al.: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60(7), 1884-1894 (2009).
40. Ehlers S: TNF and its blocked in granulomatous infections: differential modes of actin of infliximab and etanercept? Clin. Infect. Dis. 41(3), 199-203 (2005).
41. Wallis RS, Broder M, Wong J, Lee A, Hoq L: Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis. 41(3), S194-S198 (2005).
42. Reinhart K, Karzai W: Anti TNF therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29(Suppl.), 121-125 (2001).
43. Khalil AA, Hall JC, Aziz FA: Tumour necrosis factor: implications for surgical patients. ANZ J. Surg. 76, 1010-1016 (2006).
44. Askling J, Baecklund E, Granath F et al.: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann. Rheum. Dis. 68(5), 648-653 (2009).
45. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56(5), 1433-1439 (2007).
46. Leombruno JP, Einarson TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68(7), 1136-1145 (2009).
47. Askling J, van Vollenhoven RF, Granath F et al.: Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor a therapies. Does the risk change with the time since start of treatment? Arthritis Rheum. 60 (11), 3180-3189 (2009).
48. Pay S; The Society for Research and Education in Rheumatology of Turkey: Risk of cancer in Turkish patients after treatment with TNF antagonists. Rheumatology 47, 548-549 (2008).
49. Brown ER, Charles KA, Hoare SA et al.: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer. Ann. Oncol. 19, 1340-1346 (2008).
50. Danila MI, Patkar NM, Curtis JR et al.: Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr. Opin. Rheumatol. 2, 327-333 (2008).
51. Roux CH, Brocq O, Breuil V et al.: Pregnancy in rheumatology patients exposed to anti-TNF-a terapy. Rheumatology (Oxford) 46, 695-698 (2007).
52. Chen YF, Jobanputra P, Barton P: A systemic review of the effectiveness of adalumimab, etanercept, and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 1-253 (2006).
53. Wagner CL, Schantz A, Barnathan E et al.: Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev. Biol. (Basel) 112, 37-53 (2003).
54. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al.: Clinical response to adalumimab: The relationship with anti adalumimab antibodies and serum adalumimab concentration in rheumatoid arthritis. Ann. Rheum. Dis. 12, 234-236 (2007).
55. Klareskog L, Wajdula J, Yeh P et al.: Low antibody and anti etanercept antibody formation and lack of impact on clinical outcomes following 5 years of treatment with Enbrel in patients with rheumatoid arthritis. Arthritis Rheum. 52, 348 (2005).
56. Cepeda EJ, Williams FM, Ishimori ML et al.: The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann. Rheum. Dis. 67(5), 710-712 (2008).
57. Ferri C, Ferraccioli G, Ferrari D et al.: Safety of anti-tumor necrosis factor-a therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J. Rheumatol. 35(10), 1944-1949 (2008).
58. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G: Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 76(3), 308-311 (2009).
59. Li S, Kaur PP, Chan V, Berney S: Use of tumor necrosis factor-a (TNF-a) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin. Rheumatol. 28(7), 787-791 (2009).
60. Nathan DM, Angus PW, Gibson PR: Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J. Gastroenterol. Hepatol. 21(9), 1366-1371 (2006).
61. Van den Hout WB, Goekoop Ruiterman YPM, Allaart CF et al.: Additional cost of initial therapy including infliximab in patients with early rheumatoid arthritis may be compensated by the value of sustained working hours: 2 year result of the best study. Arthritis Rheum. 54, 227-228 (2006).
62. Bejarano V, Quinn M, Conaghan PG et al.: Adalumimab plus methotrexate improves work stability and reduces job loss in early rheumatoid arthritis: results of the Prevention of Work Disability (PROWD) study. Arthritis Rheum. 54, 4037-4038 (2006).
63. Sieper J: Can structural damage be prevented in ankylosing spondylitis? Curr. Opin. Rheumatol. 21(4), 335-339 (2009).
64. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM: Methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 29(3), 160-162 (2000).
65. Braun J, Brandt J, Listing J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313), 1187-1193 (2002).
66. Braun J, Brandt J, Listing J et al.: Two year maintenance of efficacy and safety of spondylitis infliximab in the treatment of ankylosing. Ann. Rheum. Dis. 64, 229-234 (2005).
67. Braun J, Deodhar A, Dijkman B et al.: Efficacy and safety of infliximab in Patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 59(9), 1270-1278 (2008).
68. Braun J, Baraliakos X, Brandt J et al.: Persistent clinical response to the anti-TNF-a antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44, 670-676 (2005).
69. Braun J, Baraliakos X, Listing J et al.: Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann. Rheum. Dis. 67, 340-345 (2008).
70. Baraliakos X, Listing J, Brandt J et al.: Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-a antibody infliximab. Rheumatology (Oxford) 46, 1450-1453 (2007).
71. Baraliakos X, Listing J, Brandt J et al.: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. 7(3), 439-444 (2005).
72. Haibel H, Rudwaleit M, Brandt HC et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum. 54(2), 678-681 (2006).
73. Van der Heijde D, Kivitz A, Schiff M et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136-2146 (2006).
74. Dougados M, Luo MP, Maksymowych WP et al.: Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum. 59(4), 553-560 (2008).
75. Revicki DA, Luo MP, Wordsworth P et al.: Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS). J. Rheumatol. 35(7), 1346-1353 (2008).
76. Van der Heijde D, Schiff MH, Sieper J et al.: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 68(6), 922-929 (2009).
77. Davis JC, van der Heijde D, Braun J et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomized, controlled trial. Arthritis Rheum. 48 (11), 3230-3236 (2003).
78. Davis JC, van der Heijde DM, Braun J et al.: Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann. Rheum. Dis. 67, 346-352 (2008).
79. Heiberg MS, Nordvåg BY, Mikkelsen K et al.: The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis a six-month, longitudinal, observational, multicenter study. Arthritis Rheum. 52(8), 2506-2512 (2005).
80. Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C: Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47, 1726-1736 (2008).
81. Zochling J, van der Heijde D, Burgos-Vargas R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 65(4), 442-452 (2006).
82. Landewé R, Rump B, van der Heijde D, van der Linden S: Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann. Rheum. Dis. 63, 530-534 (2004).
83. Pham T, Fautrel B, Dernis E et al.: Recommendations of the French Society for Rheumatology regarding TNFa antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74, 638-646 (2007).
84. Vander Cruyssen B, Ribbens C, Boonen A et al.: The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann. Rheum. Dis. 66(8), 1072-1077 (2007).
85. Pham T, Landewé R, van der Linden S et al.: An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann. Rheum. Dis. 65,1620-1625 (2006).
86. Van Der Heijde D, Han C, De Vlam K et al.: Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. 55(4), 569-574 (2006).
87. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J: Impact of anti-tumour necrosis factor a treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann. Rheum. Dis. 63, 1670-1672 (2004).
88. McLeod C, Bagust A, Boland A et al.: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11(28), 1-158 (2007).
89. Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA: Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 46(8), 1320-1328 (2007).
90. Jois RN, Leeder J, Gibb A et al.: Low-dose infliximab treatment for ankylosing spondylitis - clinically-and cost-effective. Rheumatology (Oxford) 45, 1566-1569 (2006).
91. Breban M, Ravaud P, Claudepierre P et al.: maintenance of infliximab treatment in ankylosing spondylitis results of a one-year randomized controlled trial comparing, systematic versus on-demand treatment. Arthritis Rheum. 58(1), 88-97 (2008).
92. Gossec L, Le Henanff A, M Breban M et al.: Continuation of treatment with infliximab in ankylosing spondylitis: 2-year open follow-up. Rheumatology 45, 859-862 (2006).
93. Keeling S, Oswald A, Russell AS, Maksymowych WP: Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J. Rheumatol. 33(3), 558-561 (2006).
94. Sidiropoulos P, Kritikos HD, Siakka P et al.: Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin. Exp. Rheumatol. 23(4), 513-516 (2005).
95. Li EK, Griffith JF, Lee VW et al.: Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 47, 1358-1363 (2008).
96. Rudwaleit M, Olivieri I, Boki KA et al.: Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology 48, 551-557 (2009).
97. Van der Heijde D, Pangan AL, Schiff MH et al.: Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 67, 1218-1221 (2008).
98. Cheung PP, Tymms KE, Wilson BJ et al.: Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern. Med. J. 38(6), 396-401 (2008).
99. Lambert RG, Salonen D, Rahman P et al.: Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 56(12), 4005-4014 (2007).
100. Braun J, Baraliakos X, Golder W et al.: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab evaluation of a new scoring system. Arthritis Rheum. 48(4), 1126-1136 (2003).
101. Braun J, Landewe R, Hermann KG et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 54(5), 1646-1652 (2006).
102. Sieper J, Baraliakos X, Listing J et al.: Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 44, 1525-1530 (2005).
103. Baraliakos X, Brandt J, Listing J et al.: Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 53(6), 856-863 (2005).
104. Van der Heijde D, Landewe R, Baraliakos X et al.: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58(10), 3063-3070 (2008).
105. van der Heijde D, Landewé R, Einstein S et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58(5), 1324-1331 (2008).
106. Baraliakos X, Listing J, Rudwaleit M et al.: Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann. Rheum. Dis. 66(7), 910-915 (2007).
107. Baraliakos X, Listing J, Rudwaleit M et al.: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab. Ann. Rheum. Dis. 64, 1462-1466 (2005).
108. Sieper J, Baraliakos X, Listing J et al.: Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 44, 1525-1530 (2005).
109. Braun J, Baraliakos X, Listing J et al.: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52(8), 2447-2451 (2005).
110. Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 56(10), 3248-3252 (2007).
111. Mease PJ, Gladman DD, Christopher T et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(10), 3279-3289 (2005).
112. Gladman DD, Mease PJ, Ritchlin CT et al.: Adalimumab for long-term treatment of psoriatic arthritis forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum. 56(2), 476-488 (2007).
113. Mease PJ, Ory P, Sharp JT et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 68(5), 702-709 (2009).
114. Goedkoop AY, Kraan MC, Teunissen MB et al.: Early effects of tumour necrosis factor a blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 63, 769-773 (2004).
115. Antoni C, Krueger GG, de Vlam K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150-1157 (2005).
116. Van der Heijde D, Kavanaugh A, Gladman DD et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 56(8), 2698-2707 (2007).
117. Antoni CE, Kavanaugh A, van der Heijde D et al.: Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol. 35(5), 869-876 (2008).
118. Mease PJ, Kivitz AJ, Burch FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264-2272 (2004).
119. Mease PJ, Kivitz AJ, Burch FX et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol. 33(4), 712-721 (2006).
120. Kavanaugh A, McInnes I, Mease P et al.: Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976-986 (2009).
121. Ilowite NT: Current treatment of juvenile rheumatoid arthritis. Pediatrics 109(1), 109-115 (2002).
122. Lovell DJ, Giannini EH, Reiff A et al.: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48(1), 218-226 (2003).
123. Lovell DJ, Reiff A, Jones OY et al.: Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 54(6), 1987-1994 (2006).
124. Lovell DJ, Reiff A, Ilowite NT et al.: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 58(5), 1496-1504 (2008).
125. Kuemmerle-Deschner JB, Horneff G: Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis. Rheumatol. Int. 28(2), 153-156 (2007).
126. Takei S, Groh D, Bernstein B et al.: Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J. Rheumatol. 28(7), 1677-1680 (2001).
127. Uppal SS, Hayat SJ, Raghupathy R: Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 18(8), 690-697 (2009).
128. Matsumura R, Umemiya K, Sugiyama T et al.: Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin. Exp. Rheumatol. 27(3), 416-421 (2009).
129. Tognon S, Graziani G, Marcolongo R: Anti-TNF-a therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann. NY Acad. Sci. 1110, 474-484 (2007).
130. Melikoglu M, Fresko I, Mat C et al.: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J. Rheumatol. 32(1), 98-105 (2005).
131. Iwata S, Saito K, Yamaoka K et al.: Effects of anti-TNF-a antibody infliximab in refractory entero-Behçet's disease. Rheumatology (Oxford) 48, 1012-1013 (2009).
132. Smolen JS, Han C, van der Heijde DM, Emery P et al.: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68(6), 823-827 (2009).
133. Van der Heijde D, Klareskog L, Rodriguez-Valverde V et al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54(4), 1063-1074 (2006).